RxDoctor Payments Data

Catherine Reynolds

Family · White House, TNNPI 1942599147

Payments from drug & device makers

$3,560in general payments, 2019–2025

Across 196 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$642
  • Pfizer$338
  • AstraZeneca$302
  • Otsuka America Pharmaceutical, Inc.$277
  • Novartis$204
  • AbbVie$137
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$3,560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,560 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$57,716
Medicare patients
259
Services billed
5,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$78,906
EliquisApixaban42$34,210
TrulicityDulaglutide23$26,465
XareltoRivaroxaban19$24,300
JardianceEmpagliflozin14$15,882
Tresiba Flextouch U-200Insulin Degludec13$6,779
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,179
Atorvastatin Calcium243$3,048
Omeprazole187$2,848
Rosuvastatin Calcium121$2,743
Fluticasone Propionate153$2,578
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen93$2,318
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,233
SynthroidLevothyroxine Sodium26$2,089
Gabapentin168$2,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$642$78,90660 claims
PfizerEliquis$338$34,21042 claims
Lilly USA, LLCTrulicity$134$26,46523 claims
Johnson & JohnsonXarelto$74$24,30019 claims
Boehringer IngelheimJardiance$76$15,88214 claims
AbbVieSynthroid$137$2,08926 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$1,514176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in White House

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →